Pharma Focus Asia

Cingulate and Indegene Announce Joint Commercialisation Agreement

Monday, March 13, 2023

Cingulate and Indegene announced a joint commercialisation agreement to provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD), upon approval from the U.S. Food and Drug Administration (FDA).

The agreement includes cross-functional services through an omnichannel marketing approach uniquely designed to successfully manage pre-commercial support during Cingulate’s Phase 3 clinical trials and to effectively commercialise CTx-1301 nationwide following potential FDA approval. Moreover, this agreement provides a clear path to commercialise CTx-1301, upon FDA approval, designed specifically to tackle the unmet needs of $20 billion market by providing the first true, entire-active-day treatment for ADHD.

CTx-1301's unique properties differentiate Cingulate from other products on the market, which aligns well with Indegene's multi-channel approach to physician and patient awareness.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024